AKT1 and neoplasm: Previous reports suggested that rapamycin lacked effective activity against mTORC2 and induced feedback activation of AKT survival pathways in many tumor types, including GBM [38–40], and the activation of STAT5 by mTOR inhibition was also observed in metastatic breast cancer [41].